Compare GSK plc (GSK) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard Total World Stock Index Fund ETF — how do they compare? GSK plc trades at $52.4 (market cap $101.34B), while Vanguard Total World Stock Index Fund ETF trades at $156.68. The key difference: GSK plc pays a 3.49% dividend while Vanguard Total World Stock Index Fund ETF pays none, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | VT | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $159.35 |
52-Week Low | $36.20 | $128.41 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
VT trades at $156.68, down 0.06% on the day, with a bullish technical signal driven by moving averages. The ETF offers broad global equity exposure with over 10,000 holdings, though key valuation and profitability ratios are not disclosed in the provided data. Recent news highlights comparisons with competing global ETFs, emphasizing VT's diversification and expense ratio of 0.06%.
The outlook remains positive due to strong technical momentum and global diversification benefits. Risks include expense ratio competitiveness and market volatility. Analyst sentiment is generally favorable, with institutional buying activity noted in recent filings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
